Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pentamidine/chlorpromazine

Drug Profile

Pentamidine/chlorpromazine

Alternative Names: Chlorpromazine/pentamidine; CRx-026

Latest Information Update: 23 Sep 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CombinatoRx
  • Developer Zalicus
  • Class Antiemetics; Antineoplastics; Antiprotozoals; Antipsychotics; Benzamidines; Phenothiazines
  • Mechanism of Action Apoptosis stimulants; KIF11 protein inhibitors; Mitosis inhibitors; Phosphoric monoester hydrolase inhibitors; Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 25 May 2007 CombinatoRx completes two phase I/II trials in late-stage or metastatic Solid tumours in the US
  • 21 Jul 2005 Pentamidine/chlorpromazine has been licensed to HenKan in Taiwan, China and South Korea
  • 20 Jul 2005 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top